IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics

Table 6 Comparison of symptomatic DVT incidence between IgG-class anti-PF4/heparin Ab seroconverted and non-seroconverted patients

	Incidence of symptomatic DVT (%)
Drug	seroconverted	non-seroconverted	Odds ratio (95%CI)	p value
UFH	11/34(32.4%)	5/70(7.1%)	6.217 (1.951-19.816)	0.001
LMWH	3/9(33.3%)	11/86(12.8%)	3.409 (0.743-15.642)	0.125
Fondaparinux	3/12(25.0%)	5/69(7.2%)	4.267 (0.868-20.972)	0.092
Others	3/19(15.8%)	15/75(20.0%)	0.750 (0.193-2.913)	0.481

Abbreviations: DVT; deep vein thrombosis, UFH; unfractionated heparin, LMWH; low-molecular weight heparin, 95%CI; confidence interval

ISSN: 1471-2474